22nd Century Group Expanded Tobacco Platform
The company has developed non-GMO reduced-nicotine tobacco following a French agency report on nicotine limits.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Should governments mandate lower nicotine levels in all combustible tobacco products?
22nd Century Group has expanded its tobacco platform to include non-GMO plants capable of nicotine reduction. This move follows a December 2025 report from the French health agency ANSES, which recommended nicotine limits for all combustible products.
Why it matters
Reducing nicotine content in tobacco could potentially curb smoking addiction and aid in cessation efforts. The company developed non-GMO options to align with European Union regulations regarding genetically modified organisms while targeting a significant legal market.
22nd Century Group utilizes patented technology to reduce nicotine by 95% in tobacco plants. The company expanded this platform to source reduced-nicotine tobacco without the use of genetic modification.
The players
22nd Century Group
This is a biotech company focused on plant science and tobacco harm reduction.
ANSES
The French Agency for Food, Environmental and Occupational Health and Safety provides public health recommendations.
Food and Drug Administration
This is the United States federal agency responsible for regulating tobacco products and medical research.
The details
The expansion follows the French agency ANSES recommendation that could reshape the tobacco market. By developing non-GMO versions, the company seeks to bypass feasibility concerns tied to EU rules on modified organisms while preparing for potential regulatory changes expected by the end of 2026.
Timeline
2011: The company began supplying Spectrum research cigarettes to U.S. agencies.
December 2019: The FDA authorized the VLN cigarette product line.
December 2021: The FDA granted the company a Modified Risk Tobacco Product designation.
December 5, 2025: ANSES validated its report recommending nicotine limits.
May 2026: The FDA filed the company's MRTP renewal applications for review.
The Tech Race
This development marks a transition from niche research tobacco toward mass-market commercial scaling in response to evolving health standards. It positions the company to compete within a European regulatory environment that is increasingly skeptical of genetic modification.
Consumers may eventually see lower-nicotine tobacco products available in markets regulated by the EU. This technological shift could change the composition of products available at retail, depending on the final regulatory implementation.
The takeaway
The move toward non-GMO reduced-nicotine products illustrates how biotech firms are adapting to stricter international health regulations. By focusing on non-modified alternatives, the company aims to balance scientific innovation with complex legal requirements in global markets.
What happens next
Legislative proposals for the European Union tobacco control framework are expected before the end of 2026.
Further reading
Learn more about the latest industry developments in Biotech.
Live Poll
Should governments mandate lower nicotine levels in all combustible tobacco products?
